(Reuters) -Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to ...
The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.
The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...
In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.
3d
IFLScience on MSNNasal Spray Shows Potential To Treat Traumatic Brain InjuryTBI occurs when the brain is damaged by an external force, like a nasty tackle or a hard punch (or getting pulled over by ...
The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...
When a cold leaves you stuffed up, you can get fast relief from a nasal spray. But take a minute to learn the different types and how to use them. It can make all the difference in effectively ...
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results